PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues.IC50 & Target: IC50: 10 μM (protein disulfide isomerase)In Vitro: PACMA 31 (0-10 μM; 24 hours) significantly inhibits colony formation in OVCAR-8 cells in a dose-dependent manner.In Vivo: PACMA 31 (20-200 mg/kg; i.p.; daily for 62 days) suppresses tumor growth in human ovarian cancer mouse xenografts .